Clinical Trials Logo

Clinical Trial Summary

Patients with acute coronary syndrome (MI, NSTEMI, USAP) will be included. They will be screened for statin intolernace for 6 months.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04069598
Study type Observational
Source Turkish Society of Cardiology
Contact
Status Recruiting
Phase
Start date August 26, 2019
Completion date March 31, 2020

See also
  Status Clinical Trial Phase
Completed NCT04986241 - The Association of Statins on Cardiorespiratory Fitness and Exercise Adaptation
Recruiting NCT04499859 - Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI Phase 4
Completed NCT03001076 - Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility) Phase 3
Completed NCT02988115 - Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant Phase 3
Recruiting NCT05332158 - Medicines Gaps Study N/A
Not yet recruiting NCT06381947 - Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients Phase 4
Completed NCT03874156 - MUscle Side-Effects of Atorvastatin in Coronary Patients Phase 4
Not yet recruiting NCT06262685 - Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins Phase 4
Completed NCT05806723 - Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic Men Phase 4
Active, not recruiting NCT03653663 - NIRS to Diagnose SAMS Phase 4
Completed NCT02993406 - Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo Phase 3
Completed NCT04453735 - MUscle Side-Effects of Atorvastatin in Coronary Patients (MUSE) -Follow-up Study Phase 4
Terminated NCT04507373 - 7T Magnetic Resonance Spectroscopy and Skeletal Muscle Biopsy Findings in Statin Associated Adverse Muscle Events Phase 4